Evaluation of right atrium structure and function in a rat model of monocrotaline‐induced pulmonary hypertension: Exploring the possible antiarrhythmic properties of amiodarone

Atrial arrhythmias (AA) are common in pulmonary hypertension (PH) and are closely associated with poor clinical outcomes. One of the most studied models to investigate PH is the rat model of monocrotaline (MCT) induced PH (MCT-PH). To date, little is known about right atrium (RA) function in the MCT-PH model and the propensity of RA to develop arrhythmias. Therefore, the aim of the study was to evaluate the function of the RA of control (CTRL) and MCT treated rats, and the ability of amiodarone, a classical antiarrhythmic, to prevent the occurrence of AA in the RA in MCT-PH rats. RA function was studied in MCT-PH rats 20 days after a single subcutaneous injection of MCT 50 mg/kg. The histological results indicated the presence of RA and right ventricular hypertrophy. Surface electrocardiogram demonstrated increased P wave duration, PR wave duration and QT interval in MCT rats. RA from MCT rats were more susceptible to develop ex vivo burst pacing arrhythmias when compared to CTRL. Intriguingly, amiodarone in clinical relevant concentration was not able to prevent the occurrence arrhythmias in RA from MCT-PH animals. Hence, we conclude that the rat model of MCT-PH impairs RA structure and function, and acute exposure of RA to amiodarone in clinical relevant concentration is not able to attenuate the onset of arrhythmias in the ex vivo RA preparation.

[1]  D. Roman-Campos,et al.  Ranolazine exerts atrial antiarrhythmic effects in a rat model of monocrotaline‐induced pulmonary hypertension , 2023, Basic & clinical pharmacology & toxicology.

[2]  Bin Kong,et al.  Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease , 2022, ESC heart failure.

[3]  Satoshi Higa,et al.  Role of Endothelin-1 in Right Atrial Arrhythmogenesis in Rabbits with Monocrotaline-Induced Pulmonary Arterial Hypertension , 2022, International journal of molecular sciences.

[4]  M. Humbert,et al.  2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.

[5]  Y. Protsenko,et al.  Contractile Behavior of Right Atrial Myocardium of Healthy Rats and Rats with the Experimental Model of Pulmonary Hypertension , 2022, International journal of molecular sciences.

[6]  Zhihong Liu,et al.  The spectrum and prevalence of arrhythmia in different clinical pulmonary hypertension groups in Chinese population , 2022, Clinical cardiology.

[7]  Keivan Mohammadi,et al.  Prevalence of amiodarone-induced hypothyroidism; A systematic review and meta-analysis: Amiodarone-induced hypothyroidism epidemiology. , 2022, Trends in cardiovascular medicine.

[8]  U. Schotten,et al.  Electrophysiological Consequences of Cardiac Fibrosis , 2021, Cells.

[9]  A. N. Gondim,et al.  Eugenol interacts with cardiac sodium channel and reduces heart excitability and arrhythmias. , 2021, Life sciences.

[10]  Yoshiaki Suzuki,et al.  Comparative analysis of age in monocrotaline-induced pulmonary hypertensive rats. , 2021, Journal of pharmacological sciences.

[11]  A. Santos-Miranda,et al.  Ethnic-Related Sodium Voltage-Gated Channel α Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Nav1.5 , 2021, Molecular Pharmacology.

[12]  S. Provencher,et al.  Pulmonary Disease, Pulmonary Hypertension and Atrial Fibrillation. , 2021, Cardiac electrophysiology clinics.

[13]  D. Roman-Campos,et al.  Impact of pacing frequency in amiodarone interaction with cardiomyocytes near physiological temperature in health and disease conditions , 2020, Basic & clinical pharmacology & toxicology.

[14]  J. Cruz,et al.  Reactive oxygen species and nitric oxide imbalances lead to in vivo and in vitro arrhythmogenic phenotype in acute phase of experimental Chagas disease , 2020, PLoS pathogens.

[15]  S. Nattel,et al.  Right Atrial Mechanisms of Atrial Fibrillation in a Rat Model of Right Heart Disease. , 2019, Journal of the American College of Cardiology.

[16]  Z. Mousavi,et al.  The potassium channel blocker, dalfampridine diminishes ouabain-induced arrhythmia in isolated rat atria , 2019, Archives of physiology and biochemistry.

[17]  A. Althouse,et al.  Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension , 2018, Pulmonary circulation.

[18]  T. Kolb,et al.  Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact , 2018, Pulmonary circulation.

[19]  C. Goudis.  Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. , 2017, Journal of cardiology.

[20]  L. Belardinelli,et al.  Inhibitions of late INa and CaMKII act synergistically to prevent ATX-II-induced atrial fibrillation in isolated rat right atria. , 2016, Journal of molecular and cellular cardiology.

[21]  F. Gaita,et al.  Supraventricular Arrhythmias in Patients With Pulmonary Arterial Hypertension. , 2015, The American journal of cardiology.

[22]  R. Vitorino,et al.  Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. , 2015, Pulmonary pharmacology & therapeutics.

[23]  Erland Erdmann,et al.  Clinical Impact of Atrial Fibrillation in Patients with Pulmonary Hypertension , 2012, PloS one.

[24]  L. Farkas,et al.  The monocrotaline model of pulmonary hypertension in perspective. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[25]  D. Zopf,et al.  C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats. , 2011, European journal of pharmacology.

[26]  J. M. Di Diego,et al.  Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. , 2008, Heart rhythm.

[27]  S. Sicouri,et al.  Acute In Vitro Effects of Dronedarone, an Iodine-Free Derivative, and Amiodarone, on the Rabbit Sinoatrial Node Automaticity: A Comparative Study , 2007, Journal of cardiovascular pharmacology and therapeutics.

[28]  K. Philipson,et al.  Regulation of cardiac L-type Ca2+ current in Na+-Ca2+ exchanger knockout mice: functional coupling of the Ca2+ channel and the Na+-Ca2+ exchanger. , 2007, Biophysical journal.

[29]  R. Budriesi,et al.  Novel quinolizidinyl derivatives as antiarrhythmic agents. , 2007, Journal of medicinal chemistry.

[30]  J. Bassani,et al.  Cholinergic-adrenergic antagonism in the induction of tachyarrhythmia by electrical stimulation in isolated rat atria. , 2004, Journal of molecular and cellular cardiology.

[31]  Itsuo Kodama,et al.  Short- and Long-Term Effects of Amiodarone on the Two Components of Cardiac Delayed Rectifier K+ Current , 2001, Circulation.

[32]  J. Kimura,et al.  Inhibitory effect of amiodarone on Na+/Ca2+ exchange current in guinea‐pig cardiac myocytes , 2000, British journal of pharmacology.

[33]  E. Hutchinson,et al.  VENTRICULAR WEIGHT IN CARDIAC HYPERTROPHY , 1952, British heart journal.

[34]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.